<DOC>
	<DOCNO>NCT00006224</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat patient persistent recurrent cancer cervix .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Persistent Recurrent Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity gemcitabine patient persistent recurrent nonsquamous cell carcinoma cervix fail high priority treatment protocol . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute weekly 3 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : Approximately 15-37 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis persistent recurrent nonsquamous cell carcinoma cervix fail local therapeutic measure consider incurable Eligible subtypes : Adenocarcinoma Adenosquamous carcinoma Undifferentiated carcinoma Must document disease progression Histologic confirmation original primary tumor require Bidimensionally measurable disease Ineligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Granulocyte count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT alkaline phosphatase great 3 time normal Renal : Creatinine great 1.5 mg/dL Other : No significant infection Not pregnant Fertile patient must use effective contraception No invasive malignancy within past 5 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : No prior gemcitabine At least 3 week since prior chemotherapy cervical cancer recover No 1 prior chemotherapy regimen ( single combination cytotoxic therapy ) Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy cervical cancer recover Surgery : At least 3 week since prior surgery cervical cancer recover Other : No prior cancer treatment would preclude study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>